Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo: A Phase 2A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Brief Summary:
This is a phase 2A clinical trial designed to test the pro-melanogenic and anti-inflammatory role of phosphodiesterase-4 inhibitors (PDE4i), alone and in combination with active narrow band UVB (NBUVB), in vitiligo lesions. This is a double-blind, randomized controlled trial (RCT) with six study arms. The goal is for 64 participants to be recruited and complete the study.
Actual Study Start Date: September 7, 2022
Estimated Study Completion Date: July 2023
https://beta.clinicaltrials.gov/study/NCT05298033
FAQOther Questions
- How smoking affects vitiligo?
Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....
- What tests should be done?
A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...
- What causes vitiligo?
Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.